The TOR pathway: A target for cancer therapy

Mary Ann Bjornsti, Peter J. Houghton

Research output: Contribution to journalReview articlepeer-review

1134 Scopus citations

Abstract

Rapamycin, a macrocyclic lactone, is a highly specific inhibitor of the serine/threonine protein kinase target of rapamycin (TOR). Although it is clear that TOR controls initiation of protein translation, recent results indicate that TOR is a central controller, integrating a plethora of signalling pathways that respond to growth factors and nutritional status. In addition to the role of rapamycin as an immune suppressant, emerging data indicate that genetic and metabolic changes accompanying malignant transformation might cause hypersensitivity to TOR inhibition.

Original languageEnglish (US)
Pages (from-to)335-348
Number of pages14
JournalNature Reviews Cancer
Volume4
Issue number5
DOIs
StatePublished - May 2004
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The TOR pathway: A target for cancer therapy'. Together they form a unique fingerprint.

Cite this